AI Watch: SoftBank’s $40 billion AI bet, Lilly’s $2.75 billion drug deal, and Grok’s EU setback

SoftBank has raised a $40 billion short-term loan to back its growing exposure to OpenAI, signaling confidence in a possible IPO. Eli Lilly has signed a $2.75 billion deal with Insilico Medicine to commercialize AI-developed drugs globally. In Europe, Elon Musk’s Grok faces legal restrictions over misuse of AI-generated imagery. Meanwhile, India’s Sarvam AI has launched Chanakya for secure government deployments.